Venturis Therapeutics, Inc. has 3 open IND’s with the US Food and Drug Administration and 4 preclinical programs. Each are discussed below:

Clinical Stage Programs

Drug Candidate
Indication
Status
VT-141
Vascu-Grow™
CD Foot Ulcers (Chronic Diabetic Foot Ulcers)
Phase 1
Phase 2
Phase 2
VT-141
Vascu-Grow™
CAD (Coronary Artery Disease)
VT-141
Vascu-Grow™
PAD (Peripheral Arterial Disease)

Pre-Clinical Research & Development

Drug Candidate
Indication
VT-141ED
VT-141S
Infarct Stroke
Erectile Dysfunction
VT-141D
Ischemic Disc Disease
VT-141P
Parkinson’s Disease

Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease, and peripheral artery disease.

Contact Information

2626 Cole Avenue, Suite 300
Dallas, Texas 75204

(972) 904-2029

© Copyright  2023 Venturis Therapeutics  |  All Rights Reserved